Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
2000 1
2001 1
2007 5
2008 6
2009 11
2010 9
2011 15
2012 10
2013 10
2014 12
2015 13
2016 10
2017 10
2018 10
2019 10
2020 8
2021 11
2022 5
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Results by year

Filters applied: . Clear all
Page 1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Free article. Review.
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticu …
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal …
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A. Tefferi A. Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2. Am J Hematol. 2021. PMID: 33197049 Free article. Review.
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations. ...ADVERSE MUTATIONS: SRSF2, ASXL1, and U2AF1- …
DISEASE OVERVIEW: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell-derived clonal …
Myelofibrosis biology and contemporary management.
Gangat N, Tefferi A. Gangat N, et al. Br J Haematol. 2020 Oct;191(2):152-170. doi: 10.1111/bjh.16576. Epub 2020 Mar 20. Br J Haematol. 2020. PMID: 32196650 Free article. Review.
Myelofibrosis is an enigmatic myeloproliferative neoplasm, despite noteworthy strides in understanding its genetic underpinnings. ...Our review serves to synopsise current appreciation of the pathogenesis of myelofibrosis together with emerging management strategies …
Myelofibrosis is an enigmatic myeloproliferative neoplasm, despite noteworthy strides in understanding its genetic underpinnings. ... …
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Stockklausner C, Duffert CM, Cario H, Knöfler R, Streif W, Kulozik AE; THROMKID-Plus Studiengruppe der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) and of Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH). Stockklausner C, et al. Ann Hematol. 2021 Jul;100(7):1647-1665. doi: 10.1007/s00277-021-04485-0. Epub 2021 Mar 12. Ann Hematol. 2021. PMID: 33712866 Free PMC article. Review.
Secondary thrombocytosis is a frequent secondary finding in childhood infection and inflammation. Primary hereditary thrombocytosis may be caused by germline mutations within the genes encoding key regulators of thrombopoiesis, i.e., thrombopoietin (THPO) and its receptor …
Secondary thrombocytosis is a frequent secondary finding in childhood infection and inflammation. Primary hereditary thrombocytosis m …
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.
Garmezy B, Schaefer JK, Mercer J, Talpaz M. Garmezy B, et al. Blood Rev. 2021 Jan;45:100691. doi: 10.1016/j.blre.2020.100691. Epub 2020 Apr 7. Blood Rev. 2021. PMID: 32354563 Review.
Although understanding of the pathogenesis and molecular biology of primary myelofibrosis continues to improve, treatment options are limited, and several biological features remain unexplained. ...For patients with higher-risk disease, several treatments are availa …
Although understanding of the pathogenesis and molecular biology of primary myelofibrosis continues to improve, treatment opti …
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A, Alkhateeb H, Gangat N. Tefferi A, et al. Blood Cancer J. 2023 Jul 18;13(1):108. doi: 10.1038/s41408-023-00878-8. Blood Cancer J. 2023. PMID: 37460550 Free PMC article. Review.
Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as "blast-phase MPN", is the most feared disease complication, with incidence estimates of 1-4% for essential thrombocythemia, 3-7% for polycythemia vera, and 9-13% for primary myelofibrosis …
Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as "blast-phase MPN", is the most feared disease complicatio …
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.
Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernandez-Boluda JC, Koschmieder S, Jain T, Mascarenhas J, Mesa R, Popat UR, Passamonti F, Polverelli N, Rambaldi A, Robin M, Salit RB, Schroeder T, Scott BL, Tamari R, Tefferi A, Vannucchi AM, McLornan DP, Barosi G. Kröger N, et al. Lancet Haematol. 2024 Jan;11(1):e62-e74. doi: 10.1016/S2352-3026(23)00305-8. Epub 2023 Dec 4. Lancet Haematol. 2024. PMID: 38061384 Review.
New options for medical therapy and risk scoring systems containing molecular data are leading to increased complexity in the management of patients with myelofibrosis. ...Seven domains and 18 key questions were selected through a series of questionnaires using a De …
New options for medical therapy and risk scoring systems containing molecular data are leading to increased complexity in the managem …
Diagnosis and management of prefibrotic myelofibrosis.
Rumi E, Sant'Antonio E, Boveri E, Pietra D, Cavalloni C, Roncoroni E, Astori C, Arcaini L; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Rumi E, et al. Expert Rev Hematol. 2018 Jul;11(7):537-545. doi: 10.1080/17474086.2018.1484280. Epub 2018 Jun 22. Expert Rev Hematol. 2018. PMID: 29862872 Review.
The 2016 WHO classification comprises two stages of primary myelofibrosis (PMF): early/prefibrotic primary myelofibrosis (pre-PMF) and overt fibrotic PMF (overt PMF). ...An accurate differentiation from essential thrombocythemia (ET) is pivotal because …
The 2016 WHO classification comprises two stages of primary myelofibrosis (PMF): early/prefibrotic primary myelofibr …
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A. Cervantes F, et al. Blood. 2009 Mar 26;113(13):2895-901. doi: 10.1182/blood-2008-07-170449. Epub 2008 Nov 6. Blood. 2009. PMID: 18988864 Free article.
Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of the increasing use of allogeneic stem cell transplantation and new investigational drugs. ...
Therapeutic decision-making in primary myelofibrosis (PMF) is becoming more challenging because of the increasing use o …
Myelofibrosis Treatment Algorithm 2018.
Tefferi A, Guglielmelli P, Pardanani A, Vannucchi AM. Tefferi A, et al. Blood Cancer J. 2018 Jul 31;8(8):72. doi: 10.1038/s41408-018-0109-0. Blood Cancer J. 2018. PMID: 30065290 Free PMC article. Review.
Two novel prognostic systems for primary myelofibrosis (PMF) were recently unveiled: GIPSS (genetically inspired prognostic scoring system) and MIPSS70 (mutation-enhanced international prognostic scoring system for transplant-age patients). ...GIPPS offers a lower c …
Two novel prognostic systems for primary myelofibrosis (PMF) were recently unveiled: GIPSS (genetically inspired prognostic sc …
144 results